<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04529187</url>
  </required_header>
  <id_info>
    <org_study_id>Masaryk Hospital</org_study_id>
    <nct_id>NCT04529187</nct_id>
  </id_info>
  <brief_title>Effect of Midazolam and Dexmedetomidine on Heart Function - A Randomized MRI-based Study.</brief_title>
  <acronym>MRI</acronym>
  <official_title>Effect of Midazolam and Dexmedetomidine on Heart Function - A Randomized MRI-based Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masaryk Hospital Krajská zdravotní a.s.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masaryk Hospital Krajská zdravotní a.s.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the changes in heart function, induced after sedation with midazolam or&#xD;
      dexmedetomidine, using cardiac magnetic resonance imaging (MRI).&#xD;
&#xD;
      This study is a randomized unmasked study, in which participant will be allocated by the&#xD;
      envelop method into the dexmedetomidine (DEX) group or into the midazolam (MID) group.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will test the hypothesis that the use of dexmedetomidine leads to less negative&#xD;
      impact on ventricular function compared to midazolam.&#xD;
&#xD;
      The study will include patients who will meet the inclusion criteria. A previous, yet&#xD;
      unpublished, pilot study assured that a number of 15 participants in each arm is sufficient&#xD;
      to detect statistical significant results with a statistical power of ≥ 80%. After signing&#xD;
      the informed consent, a one-session cardiac MRI will be performed in each fasting participant&#xD;
      before and after sedation administration (see arms and intervention). The following&#xD;
      parameters will be recorded: end diastolic and end systolic volume, left and right ventricle&#xD;
      stroke volume and flow velocity through the mitral valve during early and late diastole. A&#xD;
      monitor will record values of mean blood pressure, pulse and blood oxygen saturation in&#xD;
      5-minute intervals.&#xD;
&#xD;
      The acquired data will be transferred to an offline workstation for postprocessing and&#xD;
      quantification. In participants we will calculate left ventricular volumes using the&#xD;
      well-known Simpson's formula by segmenting of endocardial borders on end-diastolic and&#xD;
      end-systolic frames on every slice through the left ventricle.&#xD;
&#xD;
      The quantitative flow measurement will be performed using phase contrast quantification flow&#xD;
      mapping.&#xD;
&#xD;
      Statistical analyses will be performed using STATISTICA software (data analysis software&#xD;
      system, version 13 TIBCO Software Inc). All values will be presented as average ± standard&#xD;
      deviation. Analysis of variance for repeated measures with post hoc Fisher's LSD test will be&#xD;
      used for statistical testing of significant differences in each group and between the groups&#xD;
      before and after sedation, respectively. Significance level will be accepted at α&lt;0.05.&#xD;
&#xD;
      The participants will be monitored during sedation administration and 6 hours following&#xD;
      sedation cessation to avoid complications that could be associated with sedation&#xD;
      administration such as hypotension or rhythm disturbances.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Actual">December 31, 2019</completion_date>
  <primary_completion_date type="Actual">December 31, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in cardiac output following sedation administration</measure>
    <time_frame>5 minutes following sedation administration.</time_frame>
    <description>Using cardiac MRI stroke volume (measured in mL) of both heart ventricles will be registered prior and after sedation administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in diastolic heart function following sedation administration</measure>
    <time_frame>5 minutes following sedation administration.</time_frame>
    <description>Using cardiac MRI maximum flow velocity through the mitral valve (measured in mL/s) during early and late diastole will be measured prior and after sedation administration.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Cardiac Function</condition>
  <condition>Sedation</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <arm_group>
    <arm_group_label>DEX group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants allocated into this arm will undergo a baseline cardiac MRI. Then a dexmedetomidine infusion in a rate of of 0.7 ug.kg-1.hr-1will be initiated. After 5 minutes of dexmedetomidine therapy a control cardiac MRI will be performed to detect changes in heart function following sedation administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MID group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants allocated into this arm will undergo a baseline cardiac MRI. Then a single dose of midazolam (2 mg intravenously) will be given to each participant in this arm. After 5 minutes of midazolam administration a control cardiac MRI will be performed to detect changes in heart function following sedation administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>To monitor the changes in heart function induced after midazolam sedation using cardiac MRI.</description>
    <arm_group_label>MID group</arm_group_label>
    <other_name>Dormicum® (Roche, F. Hoffmann-La Roche Ltd Basel, Switzerland)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine</intervention_name>
    <description>To monitor the changes in heart function induced after dexmedetomidine sedation using cardiac MRI.</description>
    <arm_group_label>DEX group</arm_group_label>
    <other_name>Dexdor® (Orion Corporation, Nasdaq OMX Helsinki: ORNAV and ORNBV, Finland)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients who were admitted due to chest pain, in whom acute coronary syndrome,&#xD;
             pulmonary embolism and acute aortic syndrome were ruled out&#xD;
&#xD;
          -  Age ≥18 and ≤ 65 years&#xD;
&#xD;
          -  No contraindication to provide cardiac MRI&#xD;
&#xD;
          -  No known allergy to Midazolam or Dexmedetomidine&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  No history of heart, hepatic, renal or respiratory failure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Atrial fibrilation&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Heart Failure&#xD;
&#xD;
          -  Renal Failure&#xD;
&#xD;
          -  Hepatic disease&#xD;
&#xD;
          -  Respiratory insufficiency&#xD;
&#xD;
          -  Fertility and lactation&#xD;
&#xD;
          -  Patients who cannot cooperate or refuse to sign the consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nedal Omran, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masaryk Hospital and UJEP, Usti nad Labem, Czech Republic.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Cardiology, Masaryk Hospital and UJEP, Usti nad Labem, Czech Republic.</name>
      <address>
        <city>Ústí Nad Labem</city>
        <zip>40011</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 18, 2020</study_first_submitted>
  <study_first_submitted_qc>August 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 27, 2020</study_first_posted>
  <last_update_submitted>August 25, 2020</last_update_submitted>
  <last_update_submitted_qc>August 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Masaryk Hospital Krajská zdravotní a.s.</investigator_affiliation>
    <investigator_full_name>Nedal Omran</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

